Show simple item record

AuthorKaddoura, Rasha
AuthorMohamed Ibrahim, Mohamed Izham
AuthorAl-Amri, Maha
AuthorPrabhakaran Nair, Arun
AuthorAlharafsheh, Ahmad
AuthorAlyafei, Sumaya Alsaadi
AuthorAlbakri, Mutaz
Available date2024-04-25T06:20:12Z
Publication Date2024
Publication NameFrontiers in Medicine
ResourceScopus
ISSN2296858X
URIhttp://dx.doi.org/10.3389/fmed.2024.1326156
URIhttp://hdl.handle.net/10576/54238
AbstractBackground: Coronavirus disease 2019 (COVID-19) associated hypertriglyceridemia was observed among patients admitted to intensive care units (ICU) in Qatar. This study aimed to describe COVID-19-associated-hypertriglyceridemia in ICU patients and the impact of treating hypertriglyceridemia on clinical outcomes. Methods: A retrospective observational cohort study of adult patients who were admitted to the ICU with a confirmed diagnosis of COVID-19 pneumonia according to the World Health Organization criteria. Hypertriglyceridemia was defined as triglyceride level of 1.7 mmol/L (≥150 mg/dL) and severe hypertriglyceridemia as fasting TG of ≥5.6 mmol/L (≥500 mg/dL). Results: Of 1,234 enrolled patients, 1,016 (82.3%) had hypertriglyceridemia. Median age was 50 years and 87.9% were males. Patients with hypertriglyceridemia showed significantly longer time to COVID-19 recovery, ICU and hospital stay, and time to death (29.3 vs. 16.9 days) without a difference in mortality between groups. Of patients with hypertriglyceridemia, 343 (33.8%) received treatment (i.e., fibrate and/or omega-3). Patients in treatment group showed longer time to COVID-19 recovery and hospital stay with no difference in death rates in comparison with those in no-treatment group. Relatively older patients were less likely to experience hypertriglyceridemia (odd ratio (OR) 0.976; 95% CI: 0.956, 0.995) or to receive treatment (OR 0.977; 95% CI: 0.960, 0.994). Whereas patients who received tocilizumab were more likely to experience high TG level (OR 3.508; 95% CI: 2.046, 6.015) and to receive treatment for it (OR 2.528; 95% CI: 1.628, 3.926). Conclusion: Hypertriglyceridemia associated with COVID-19 did not increase death rate, but prolonged time to death and length of stay. Treating hypertriglyceridemia did not translate into improvement in clinical outcomes including mortality.
SponsorThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. Open access publication fee funding was provided by Academic Health System at Hamad Medical Corporation.
Languageen
PublisherFrontiers Media SA
SubjectCOVID-19
fenofibrate
hypertriglyceridemia
omega-3
SARS-CoV-2
triglycerides
TitleCOVID-19-associated hypertriglyceridemia and impact of treatment
TypeArticle
Volume Number11
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record